SANTA MONICA, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months ended September 30, 2021 ,

SANTA MONICA, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that members of the company’s senior management team will participate in the 12 th  Jefferies

Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge 1 This designation enables early and frequent communication with the FDA, in addition to the potential for a rolling submission of

SANTA MONICA, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced the publication of a manuscript entitled “ Treatment of Overdose in the Synthetic Opioid Era ”

SANTA MONICA, Calif. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates

SANTA MONICA, Calif. , Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company’s senior management team will participate in the following virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment

SANTA MONICA, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021 , and

SANTA MONICA, Calif. , July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2021

SANTA MONICA, Calif. , July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards

Mr. Ruth led the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdose He joins Opiant at a time when the Company is developing and moving towards potential commercialization of OPNT003, nasal nalmefene, a novel investigational